A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.

Camille Catherine Jackson,Leigh A. Cantrell,Britt K. Erickson,Kathleen N. Moore,Linda R. Duska,Debra L. Richardson,Lisa M. Landrum,Laura L. Holman,Joan L. Walker,Robert S. Mannel,Katherine M. Moxley,Lurdes Queimado,Kai Ding,Andrew J. Cohoon,Sara K. Vesely,L.E. Dockery

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.

2021

Camille Catherine Jackson
Leigh A. Cantrell
Britt K. Erickson
Kathleen N. Moore
Linda R. Duska
Debra L. Richardson
Lisa M. Landrum
Laura L. Holman
Joan L. Walker
Robert S. Mannel
Katherine M. Moxley
Lurdes Queimado
Kai Ding
Andrew J. Cohoon
Sara K. Vesely
L.E. Dockery

5527Background: Treatment options for patients with recurrent cervical and endometrial cancer remain limited. Even with optimum care, median survival has stalled at 12-17 months. The PARP inhibitor...

Keywords:

Endometrial cancer
Bevacizumab
median survival
Recurrent Carcinoma
Endometrium
Medicine
Oncology
Internal medicine
Cervix
Rucaparib
PARP inhibitor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations